Lunestaeszopiclone
According to the FDA label: 1 INDICATIONS & USAGE Eszopiclone tablets are indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, eszopiclone tablets administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration.
25,088 adverse event reports submitted to the FDA (2005–2026)
Top Reported Adverse Events
The most frequently reported events in association with Lunesta in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.
Show these terms with plain-language definitions
Tap any term below for a plain-language definition.
Drug Ineffective 4,848 reports
A report that the medication did not work as expected for the person taking it. This is a reporting category, not a sign the drug is defective. It simply means someone felt it was not helping their condition.
Full definition in the glossary →Insomnia 3,892 reports
Difficulty falling asleep or staying asleep.
Full definition in the glossary → See all drugs reporting this event →Dysgeusia 3,854 reports
A distorted or altered sense of taste, such as a persistent metallic taste.
Full definition in the glossary →Nausea 1,405 reports
The feeling of sickness in your stomach that often comes before vomiting.
Full definition in the glossary → See all drugs reporting this event →- Middle Insomnia 1,214 reports
Fatigue 1,197 reports
Extreme tiredness or lack of energy that does not improve with rest.
Full definition in the glossary → See all drugs reporting this event →Headache 1,175 reports
Pain in the head or upper neck.
Full definition in the glossary → See all drugs reporting this event →Somnolence 886 reports
Drowsiness or strong sleepiness.
Full definition in the glossary → See all drugs reporting this event →Dizziness 880 reports
A feeling of being lightheaded, unsteady, or like the room is spinning.
Full definition in the glossary → See all drugs reporting this event →Anxiety 861 reports
A feeling of worry, nervousness, or unease.
Full definition in the glossary → See all drugs reporting this event →- Initial Insomnia 856 reports
Pain 817 reports
A general report of physical discomfort, used when no more specific location is given.
Full definition in the glossary →Diarrhoea 760 reports
Loose or watery bowel movements, often frequent. Also spelled diarrhea in American English.
Full definition in the glossary → See all drugs reporting this event →Depression 717 reports
A persistent low mood, loss of interest, or feelings of sadness. If you are struggling, the 988 Suicide and Crisis Lifeline (call or text 988 in the US) is available 24 hours a day.
Full definition in the glossary → See all drugs reporting this event →Fall 658 reports
A report that the person fell down. Falls are tracked because they can signal issues like dizziness, weakness, or balance problems.
Full definition in the glossary →
Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.
Who Is Reporting
Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.
By Sex
View reporter sex data as a table
| Sex | Reports |
|---|---|
| Female | 15,541 |
| Male | 8,096 |
| Unknown | 130 |
By Age Group
View age group data as a table
| Age group | Reports |
|---|---|
| 0-17 | 195 |
| 18-34 | 1,359 |
| 35-49 | 3,738 |
| 50-64 | 5,773 |
| 65-74 | 2,985 |
| 75+ | 2,709 |
This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.
Reported Outcomes
Outcomes recorded in FAERS reports that included Lunesta. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.
View outcome data as a table
| Outcome | Reports |
|---|---|
| Non-Serious | 15,063 |
| Other Serious | 6,386 |
| Hospitalization | 4,610 |
| Death | 1,671 |
| Life-Threatening | 567 |
| Disability | 452 |
Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.
Report Volume Over Time
Number of FAERS reports received per quarter for Lunesta. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.
View report trend as a table
| Year | Reports |
|---|---|
| 2005 | 2,348 |
| 2006 | 4,423 |
| 2007 | 2,928 |
| 2008 | 481 |
| 2009 | 527 |
| 2010 | 728 |
| 2011 | 547 |
| 2012 | 718 |
| 2013 | 654 |
| 2014 | 659 |
| 2015 | 1,010 |
| 2016 | 1,374 |
| 2017 | 1,122 |
| 2018 | 1,232 |
| 2019 | 1,148 |
| 2020 | 1,041 |
| 2021 | 782 |
| 2022 | 822 |
| 2023 | 737 |
| 2024 | 825 |
| 2025 | 804 |
| 2026 (partial) | 178 |
The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.
Medications commonly reported with Lunesta
In FDA adverse event reports that mention Lunesta, these medications appeared most often in the same report.
- Zolpidem (2,469 reports)
- Gabapentin (2,311 reports)
- Alprazolam (2,133 reports)
- Ergocalciferol (2,055 reports)
- Duloxetine (1,942 reports)
This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.
Related Drugs
Other medications with similar adverse event profiles in FDA FAERS reports.
Data Source
This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.
View this data on the FDA website →Data last updated: June 2026